Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of XC001 as adjunctive therapy in patients with coronary artery bypass grafting (CABG)

Next Previous
X
Search
Trial Profile

A Phase 2 study of XC001 as adjunctive therapy in patients with coronary artery bypass grafting (CABG)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encoberminogene rezmadenovec (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Sponsors XyloCor Therapeutics

    • Most Recent Events

    • 10 Jul 2024 According to XyloCor Therapeutics media release, the company have entered into a licensing agreement under which XyloCor has rights to the Extroducer Infusion Catheter System , a first-in-class endovascular device designed to deliver advanced therapies directly into the heart; XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of XC001
    • 29 Jul 2021 New trial record
    • 27 Jul 2021 According to XyloCor Therapeutics media release, the company plans to submit study to the U.S. Food and Drug Administration (FDA) to start this study in 2H21

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top